HER2-positive Gastric Cancer- Pipeline Insight, 2025
Description
DelveInsight’s, “HER2-positive Gastric Cancer- Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in HER2-positive Gastric Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
HER2-positive Gastric Cancer: Overview
Gastric cancer is the sixth most common cancer and the third most common cause of cancer-related death in the world. Early gastric cancer has no associated symptoms; however, some patients with incidental complaints are diagnosed with early gastric cancer. Most symptoms of gastric cancer reflect advanced disease. All physical signs in gastric cancer are late events. In some people with stomach cancer, the cancer cells have too much of a growth-promoting protein called HER2 on their surface. Cancers with increased levels of HER2 are called HER2-positive. Drugs that target the HER2 protein can often be helpful in treating these cancers. Unfortunately, only a minority of patients with gastric cancer who undergo surgical resection will be cured of their disease. Most patients have a recurrence. HER2, also known as ErbB2/Neu, belongs to the EGFR family and is located on human chromosome 17 (17q21); this gene encodes a 185 kDa transmembrane glycoprotein (p185). EGFR family members include HER1, HER2, HER3, and HER4, which are composed of three parts: an extracellular ligand-binding domain, a transmembrane domain, and an intracellular tyrosine kinase domain.
Stomach cancer doesn’t typically cause symptoms during the early stages. Even the most common early signs of stomach cancer — often unexplained weight loss and stomach pain — don’t usually show up until the cancer is more advanced. Symptoms of stomach cancer include, loss of appetite, trouble swallowing, fatigue or weakness, nausea and vomiting, unexplained weight loss, heartburn and indigestion. Stomach cancer forms when there’s a genetic mutation (change) in the DNA of your stomach cells. DNA is the code that tells cells when to grow and when to die. Because of the mutation, the cells grow rapidly and eventually form a tumor instead of dying.
The doctor will review the medical history, ask about the symptoms and perform a physical exam that may involve feeling for a mass in stomach. They may order several tests to diagnose and stage stomach cancer. Staging allows doctor to assess how much the cancer has spread with stomach cancer, staging ranges from 0 (zero) to IV (four). Stage 0 means the cancer hasn’t spread beyond stomach lining. Stage IV means that it’s spread to other organs. The other diagnostic tests include upper endoscopy, endoscopic ultrasound, radiologic tests, blood tests and laparoscopy.
Treatment depends on how far the cancer’s spread, health and treatment preferences. It often involves a care team that includes primary care provider, a cancer specialist (oncologist) and a gastrointestinal specialist (gastroenterologist). They can advise on treatment options. The treatment plans also include surgery upper endoscopy, gastrectomy, chemotherapy, radiation, targeted drug therapy, immunotherapy.
""HER2-positive Gastric Cancer- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the HER2-positive Gastric Cancer pipeline landscape is provided which includes the disease overview and HER2-positive Gastric Cancer treatment guidelines. The assessment part of the report embraces, in depth HER2-positive Gastric Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, HER2-positive Gastric Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the HER2-positive Gastric Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
HER2-positive Gastric Cancer Emerging Drugs
Further product details are provided in the report……..
HER2-positive Gastric Cancer: Therapeutic Assessment
This segment of the report provides insights about the different HER2-positive Gastric Cancer drugs segregated based on following parameters that define the scope of the report, such as:
HER2-positive Gastric Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses HER2-positive Gastric Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging HER2-positive Gastric Cancer drugs.
HER2-positive Gastric Cancer Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
HER2-positive Gastric Cancer: Overview
Gastric cancer is the sixth most common cancer and the third most common cause of cancer-related death in the world. Early gastric cancer has no associated symptoms; however, some patients with incidental complaints are diagnosed with early gastric cancer. Most symptoms of gastric cancer reflect advanced disease. All physical signs in gastric cancer are late events. In some people with stomach cancer, the cancer cells have too much of a growth-promoting protein called HER2 on their surface. Cancers with increased levels of HER2 are called HER2-positive. Drugs that target the HER2 protein can often be helpful in treating these cancers. Unfortunately, only a minority of patients with gastric cancer who undergo surgical resection will be cured of their disease. Most patients have a recurrence. HER2, also known as ErbB2/Neu, belongs to the EGFR family and is located on human chromosome 17 (17q21); this gene encodes a 185 kDa transmembrane glycoprotein (p185). EGFR family members include HER1, HER2, HER3, and HER4, which are composed of three parts: an extracellular ligand-binding domain, a transmembrane domain, and an intracellular tyrosine kinase domain.
Stomach cancer doesn’t typically cause symptoms during the early stages. Even the most common early signs of stomach cancer — often unexplained weight loss and stomach pain — don’t usually show up until the cancer is more advanced. Symptoms of stomach cancer include, loss of appetite, trouble swallowing, fatigue or weakness, nausea and vomiting, unexplained weight loss, heartburn and indigestion. Stomach cancer forms when there’s a genetic mutation (change) in the DNA of your stomach cells. DNA is the code that tells cells when to grow and when to die. Because of the mutation, the cells grow rapidly and eventually form a tumor instead of dying.
The doctor will review the medical history, ask about the symptoms and perform a physical exam that may involve feeling for a mass in stomach. They may order several tests to diagnose and stage stomach cancer. Staging allows doctor to assess how much the cancer has spread with stomach cancer, staging ranges from 0 (zero) to IV (four). Stage 0 means the cancer hasn’t spread beyond stomach lining. Stage IV means that it’s spread to other organs. The other diagnostic tests include upper endoscopy, endoscopic ultrasound, radiologic tests, blood tests and laparoscopy.
Treatment depends on how far the cancer’s spread, health and treatment preferences. It often involves a care team that includes primary care provider, a cancer specialist (oncologist) and a gastrointestinal specialist (gastroenterologist). They can advise on treatment options. The treatment plans also include surgery upper endoscopy, gastrectomy, chemotherapy, radiation, targeted drug therapy, immunotherapy.
""HER2-positive Gastric Cancer- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the HER2-positive Gastric Cancer pipeline landscape is provided which includes the disease overview and HER2-positive Gastric Cancer treatment guidelines. The assessment part of the report embraces, in depth HER2-positive Gastric Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, HER2-positive Gastric Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence HER2-positive Gastric Cancer R&D. The therapies under development are focused on novel approaches to treat/improve HER2-positive Gastric Cancer.
This segment of the HER2-positive Gastric Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
HER2-positive Gastric Cancer Emerging Drugs
- SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
- Cinrebafusp alfa: Pieris Pharmaceuticals
- BI-1607: BioInvent International
Further product details are provided in the report……..
HER2-positive Gastric Cancer: Therapeutic Assessment
This segment of the report provides insights about the different HER2-positive Gastric Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in HER2-positive Gastric Cancer
- There are approx. 20+ key companies which are developing the therapies for HER2-positive Gastric Cancer. The companies which have their HER2-positive Gastric Cancer drug candidates in the most advanced stage, i.e. phase III include, Jiangsu HengRui Medicine Co., Ltd.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
HER2-positive Gastric Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses HER2-positive Gastric Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging HER2-positive Gastric Cancer drugs.
HER2-positive Gastric Cancer Report Insights
- HER2-positive Gastric Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing HER2-positive Gastric Cancer drugs?
- How many HER2-positive Gastric Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of HER2-positive Gastric Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the HER2-positive Gastric Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for HER2-positive Gastric Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- Jiangsu HengRui Medicine Co., Ltd.
- Pieris Pharmaceuticals
- BioInvent International
- Daiichi Sankyo|AstraZeneca
- Shanghai JMT-Bio Inc.
- Acepodia Biotech, Inc.
- Klus Pharma Inc.
- Carisma Therapeutics Inc
- Novartis Pharmaceuticals
- Celularity Incorporated
- Hoffmann-La Roche
- DualityBio Inc.
- Shanghai Miracogen Inc.
- Bavarian Nordic
- SHR-A1811
- Cinrebafusp alfa
- BI-1607
- Trastuzumab deruxtecan
- KN026
- ACE1702
- A166
- CT-0508
- LJM716
- CYNK-101
- Atezolizumab
- DB-1303
- MRG002
- TAEK-VAC-HerBy
Table of Contents
80 Pages
- Introduction
- Executive Summary
- HER2-positive Gastric Cancer: Overview
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- HER2-positive Gastric Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Cinrebafusp alfa: Pieris Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- BI-1607: BioInvent International
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- HER2-positive Gastric Cancer Key Companies
- HER2-positive Gastric Cancer Key Products
- HER2-positive Gastric Cancer- Unmet Needs
- HER2-positive Gastric Cancer- Market Drivers and Barriers
- HER2-positive Gastric Cancer- Future Perspectives and Conclusion
- HER2-positive Gastric Cancer Analyst Views
- HER2-positive Gastric Cancer Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
